The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1558
OTC Brimonidine (Lumify) for Ocular Redness
The full article is available to subscribers Subscriber Login   

The FDA has approved an over-the-counter (OTC) 0.025% ophthalmic formulation of the selective alpha2-adrenergic agonist brimonidine tartrate (Lumify – Bausch & Lomb) for treatment of ocular redness in adults and children ≥5 years old. Lumify is the first brimonidine product to be approved for OTC use.

PRESCRIPTION BRIMONIDINE PRODUCTS ― Brimonidine is available by prescription in higher-strength formulations both alone (Alphagan-P, and others) and in combinations with the beta blocker timolol (Combigan) and the carbonic anhydrase inhibitor brinzolamide (Simbrinza)1 for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Brimonidine is also available by prescription in a topical gel formulation (Mirvaso) for treatment of the facial erythema of ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: OTC Brimonidine (Lumify) for Ocular Redness
Article code: 1558c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian